Arena Updates Etrasimod Timelines, Introduces New Drug Candidate

Late-Stage S1P Modulator Data Due Later In 2021, Early In 2022

CEO Amit Munshi told the J.P. Morgan meeting the company will double the size of its clinical-stage cardiovascular disease pipeline with the addition of temanogrel.

Arena Pharmaceuticals, Inc. CEO Amit Munshi provided assurances during the J.P. Morgan Healthcare Conference on 13 January that the company is intensely focused on the initial opportunity for its selective S1P receptor modulator etrasimod in ulcerative colitis. But with Phase III data in UC a year or more away, the company offered up news of a new drug candidate and revealed updated timelines for etrasimod and other clinical-stage programs.

Munshi spent the bulk of his prepared remarks talking about temanogrel, an internally discovered 5-HT2A antagonist that the company plans to take into clinical development for the treatment of coronary...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

29 May 2025

• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

29 May 2025

• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

Loss Of Exclusivity Product Launches To Fuel Aurobindo’s FY26 Europe Growth

29 May 2025

• By Vibha Ravi

Aurobindo is banking on launches of loss of exclusivity products and biosimilars to fuel sales in Europe as it awaits a US announcement on tariffs and predicts high single-digit growth overall during FY26 for now

Korea Q1 Roundup: Mixed Earnings, Gearing For Possible US Tariffs

29 May 2025

• By Jung Won Shin

South Korean biopharma companies report a mostly solid first quarter, marked by US growth for original drugs, with several also making preparations for possible US pharma tariffs.